Activity

  • For advanced biliary tract cancer patients that also have reduced kidney function (as measured by Creatinine Clearance (CCr) between 50-80ml/min), this study presented January 18, 2019 showed that gemcitabine (GEM) plus S-1 (GS) was better in terms of overall survival, progression free survival, and blood counts than the typical standard of care for 1st line treatment, which is GEM plus cisplatin (GC). Accordingly, ASCO is considering gemcitabine (GEM) plus S-1 (GS) might be recommended for the population with lower renal function in the treatment for advanced biliary tract cancer.